Head to Head Review: Calliditas Therapeutics AB (publ) (NASDAQ:CALT) vs. PhaseBio Pharmaceuticals (NASDAQ:PHAS)

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) and PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Analyst Ratings

This is a breakdown of current ratings for Calliditas Therapeutics AB (publ) and PhaseBio Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0	0	3	0	3.00
PhaseBio Pharmaceuticals	0	0	3	0	3.00

Calliditas Therapeutics AB (publ) presently has a consensus price target of $62.00, indicating a potential upside of 239.73%. PhaseBio Pharmaceuticals has a consensus price target of $12.50, indicating a potential upside of 900.00%. Given PhaseBio Pharmaceuticals’ higher probable upside, analysts clearly believe PhaseBio Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Insider and Institutional Ownership

3.5% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 62.4% of PhaseBio Pharmaceuticals shares are held by institutional investors. 9.0% of PhaseBio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Calliditas Therapeutics AB (publ) has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, PhaseBio Pharmaceuticals has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Valuation & Earnings

This table compares Calliditas Therapeutics AB (publ) and PhaseBio Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$26.74 million	17.86	-$58.33 million	($2.26)	-8.08
PhaseBio Pharmaceuticals	$10.83 million	5.62	-$131.07 million	($3.03)	-0.41

Calliditas Therapeutics AB (publ) has higher revenue and earnings than PhaseBio Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Calliditas Therapeutics AB (publ) and PhaseBio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	N/A	-44.42%	-33.46%
PhaseBio Pharmaceuticals	N/A	N/A	-154.33%

Summary

PhaseBio Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 6 of the 11 factors compared between the two stocks.

Calliditas Therapeutics AB (publ) Company Profile (Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.

PhaseBio Pharmaceuticals Company Profile (Get Rating)

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.